Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors.
Аннотация
Renin-angiotensin-aldosterone system (RAAS) blockade has been a mainstay of therapy in cardiovascular and kidney disease for nearly 30 years. Despite the development of multiple drug classes designed to intervene along the RAAS pathway, the residual risk for the totality of adverse cardiorenal outcomes (cardiorenal disease) remains substantial. Dysregulation of aldosterone biosynthesis has pathophysiological consequences that are associated with cardiovascular and kidney damage. Aldosterone synthase inhibitors (ASi) provide a mechanism to decrease aldosterone production. These agents may help to reduce residual risk in cardiorenal disease. Preliminary evidence from ASi clinical trials is encouraging, with demonstrated efficacy in improving blood pressure control and decreasing albuminuria in chronic kidney disease. Their therapeutic potential in improving cardiorenal outcomes is being investigated further in ongoing phase III trials where ASi agents are given as monotherapy or with an SGLT2 inhibitor, and these data will be available over the coming months and years. ASi agents may be a new evidence-based addition to the cardiorenal drug armamentarium.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.